Twenty years after ACEIs and ARBs

Emerging treatment strategies for diabetic nephropathy

Stacy Johnson, Robert F. Spurney

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Diabetic nephropathy (DN) is a serious complication of both type 1 and type 2 diabetes mellitus. The disease is now the most common cause of end-stage kidney disease (ESKD) in developed countries, and both the incidence and prevalence of diabetes mellitus is increasing worldwide. Current treatments are directed at controlling hyperglycemia and hypertension, as well as blockade of the renin angiotensin system with angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers. Despite these therapies, DN progresses to ESKD in many patients. As a result, much interest is focused on developing new therapies. It has been over two decades since ACEIs were shown to have beneficial effects in DN independent of their blood pressure-lowering actions. Since that time, our understanding of disease mechanisms in DN has evolved. In this review, we summarize major cell signaling pathways implicated in the pathogenesis of diabetic kidney disease, as well as emerging treatment strategies. The goal is to identify promising targets that might be translated into therapies for the treatment of patients with diabetic kidney disease.

Original languageEnglish (US)
Pages (from-to)F807-F820
JournalAmerican Journal of Physiology - Renal Physiology
Volume309
Issue number10
DOIs
StatePublished - Jan 1 2015

Fingerprint

Diabetic Nephropathies
Angiotensin-Converting Enzyme Inhibitors
Chronic Kidney Failure
Therapeutics
Angiotensin Receptor Antagonists
Renin-Angiotensin System
Type 1 Diabetes Mellitus
Developed Countries
Hyperglycemia
Type 2 Diabetes Mellitus
Diabetes Mellitus
Blood Pressure
Hypertension
Incidence

All Science Journal Classification (ASJC) codes

  • Physiology
  • Urology

Cite this

Twenty years after ACEIs and ARBs : Emerging treatment strategies for diabetic nephropathy. / Johnson, Stacy; Spurney, Robert F.

In: American Journal of Physiology - Renal Physiology, Vol. 309, No. 10, 01.01.2015, p. F807-F820.

Research output: Contribution to journalReview article

@article{693a3418b16a4db285bf64749c280c6e,
title = "Twenty years after ACEIs and ARBs: Emerging treatment strategies for diabetic nephropathy",
abstract = "Diabetic nephropathy (DN) is a serious complication of both type 1 and type 2 diabetes mellitus. The disease is now the most common cause of end-stage kidney disease (ESKD) in developed countries, and both the incidence and prevalence of diabetes mellitus is increasing worldwide. Current treatments are directed at controlling hyperglycemia and hypertension, as well as blockade of the renin angiotensin system with angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers. Despite these therapies, DN progresses to ESKD in many patients. As a result, much interest is focused on developing new therapies. It has been over two decades since ACEIs were shown to have beneficial effects in DN independent of their blood pressure-lowering actions. Since that time, our understanding of disease mechanisms in DN has evolved. In this review, we summarize major cell signaling pathways implicated in the pathogenesis of diabetic kidney disease, as well as emerging treatment strategies. The goal is to identify promising targets that might be translated into therapies for the treatment of patients with diabetic kidney disease.",
author = "Stacy Johnson and Spurney, {Robert F.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1152/ajprenal.00266.2015",
language = "English (US)",
volume = "309",
pages = "F807--F820",
journal = "American Journal of Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "10",

}

TY - JOUR

T1 - Twenty years after ACEIs and ARBs

T2 - Emerging treatment strategies for diabetic nephropathy

AU - Johnson, Stacy

AU - Spurney, Robert F.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Diabetic nephropathy (DN) is a serious complication of both type 1 and type 2 diabetes mellitus. The disease is now the most common cause of end-stage kidney disease (ESKD) in developed countries, and both the incidence and prevalence of diabetes mellitus is increasing worldwide. Current treatments are directed at controlling hyperglycemia and hypertension, as well as blockade of the renin angiotensin system with angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers. Despite these therapies, DN progresses to ESKD in many patients. As a result, much interest is focused on developing new therapies. It has been over two decades since ACEIs were shown to have beneficial effects in DN independent of their blood pressure-lowering actions. Since that time, our understanding of disease mechanisms in DN has evolved. In this review, we summarize major cell signaling pathways implicated in the pathogenesis of diabetic kidney disease, as well as emerging treatment strategies. The goal is to identify promising targets that might be translated into therapies for the treatment of patients with diabetic kidney disease.

AB - Diabetic nephropathy (DN) is a serious complication of both type 1 and type 2 diabetes mellitus. The disease is now the most common cause of end-stage kidney disease (ESKD) in developed countries, and both the incidence and prevalence of diabetes mellitus is increasing worldwide. Current treatments are directed at controlling hyperglycemia and hypertension, as well as blockade of the renin angiotensin system with angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers. Despite these therapies, DN progresses to ESKD in many patients. As a result, much interest is focused on developing new therapies. It has been over two decades since ACEIs were shown to have beneficial effects in DN independent of their blood pressure-lowering actions. Since that time, our understanding of disease mechanisms in DN has evolved. In this review, we summarize major cell signaling pathways implicated in the pathogenesis of diabetic kidney disease, as well as emerging treatment strategies. The goal is to identify promising targets that might be translated into therapies for the treatment of patients with diabetic kidney disease.

UR - http://www.scopus.com/inward/record.url?scp=84947232947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947232947&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00266.2015

DO - 10.1152/ajprenal.00266.2015

M3 - Review article

VL - 309

SP - F807-F820

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 1931-857X

IS - 10

ER -